{"id":"1a297ada-de19-5267-a901-38f6c0463a85","stable_key":"b428117d-3a8c-5e74-8711-168153e19545:aspartame-formulation-aspartate","predicate":"has_formulation_dependent_effect_on","statement":"Peak plasma aspartate was higher and earlier with 3 g solution than capsules: 26.2 versus 10.4 micromol/L.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"01df22c8-8be9-580f-bc37-ea4fff47a4cf","mechanism_event_label":"The other amino-acid product also shows formulation effects.","subject":{"id":"15bd1664-9d4b-514f-ab83-87274a67673f","slug":"aspartame","display_name":"Aspartame","entity_type_key":"small_molecule"},"object":{"id":"165e88f7-306b-5cfa-af5e-39693cfefda7","slug":"plasma-aspartate-concentration","display_name":"Plasma aspartate concentration","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"01df22c8-8be9-580f-bc37-ea4fff47a4cf","stable_key":"b428117d-3a8c-5e74-8711-168153e19545:aspartame-formulation-aspartate-event","event_type":"observed_relationship","label":"The other amino-acid product also shows formulation effects.","description":"Peak plasma aspartate was higher and earlier with 3 g solution than capsules: 26.2 versus 10.4 micromol/L.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"15bd1664-9d4b-514f-ab83-87274a67673f","slug":"aspartame","display_name":"Aspartame","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"165e88f7-306b-5cfa-af5e-39693cfefda7","slug":"plasma-aspartate-concentration","display_name":"Plasma aspartate concentration","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"0a0923d3-72b7-5d6a-bf3a-5a7a3071a09b","slug":"l-aspartate","display_name":"L-Aspartate","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Same human comparison.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Plasma is not synaptic aspartate.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Aspartame collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"aspartame","display_name":"Aspartame","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"The other amino-acid product also shows formulation effects.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Plasma amino acid concentrations in normal adults administered aspartame in capsules or solution: lack of bioequivalence. · 1987 · https://pubmed.ncbi.nlm.nih.gov/3574137/ · DOI 10.1016/0026-0495(87)90052-7","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"70572d84-417f-57b4-b23d-25fc9822d7d9","evidence_kind":"source_excerpt","locator":"Lines 98-104","start_line":98,"end_line":104,"excerpt":"## aspartame-formulation-aspartate\nThe other amino-acid product also shows formulation effects.\nPeak plasma aspartate was higher and earlier with 3 g solution than capsules: 26.2 versus 10.4 micromol/L.\nModel: Same human comparison.\nLimitations: Plasma is not synaptic aspartate.\nEvidence access: Primary abstract\nPlasma amino acid concentrations in normal adults administered aspartame in capsules or solution: lack of bioequivalence. · 1987 · https://pubmed.ncbi.nlm.nih.gov/3574137/ · DOI 10.1016/0026-0495(87)90052-7","model_system":"Same human comparison.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"2bba7d36-993f-5ba7-acaf-2e4d573527ed","stable_key":"import-b428117d-3a8c-5e74-8711-168153e19545","title":"Aspartame: digestion, taste, metabolite dependencies and experimental signaling (2026-09-20)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"21cfc6808062c6ea1fb5d34128bcd005d31f0f6c0d63484794238db77d32ae97","revision_id":"1255dda8-df99-5d4b-a65b-4144c47d7d9b","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}